%0 Journal Article
%A Herling, Carmen D
%A Coombes, Kevin R
%A Benner, Axel
%A Bloehdorn, Johannes
%A Barron, Lynn L
%A Abrams, Zachary B
%A Majewski, Tadeusz
%A Bondaruk, Jolanta E
%A Bahlo, Jasmin
%A Fischer, Kirsten
%A Hallek, Michael
%A Stilgenbauer, Stephan
%A Czerniak, Bogdan A
%A Oakes, Christopher C
%A Ferrajoli, Alessandra
%A Keating, Michael J
%A Abruzzo, Lynne V
%T Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
%J The lancet  / Oncology Oncology
%V 20
%N 11
%@ 1470-2045
%C London
%I The Lancet Publ. Group
%M DKFZ-2019-02341
%P 1576-1586
%D 2019
%Z 20(11):1576-1586
%X Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31582354
%R 10.1016/S1470-2045(19)30503-0
%U https://inrepo02.dkfz.de/record/147215